Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus. / Buus, Terkild Brink; Schmidt, Jonas Damgård; Bonefeld, Charlotte Menné; Geisler, Carsten; Lauritsen, Jens Peter Holst.

In: OncoTarget, Vol. 7, No. 15, 29.03.2016, p. 19341-19354.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Buus, TB, Schmidt, JD, Bonefeld, CM, Geisler, C & Lauritsen, JPH 2016, 'Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus', OncoTarget, vol. 7, no. 15, pp. 19341-19354. https://doi.org/10.18632/oncotarget.8464

APA

Buus, T. B., Schmidt, J. D., Bonefeld, C. M., Geisler, C., & Lauritsen, J. P. H. (2016). Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus. OncoTarget, 7(15), 19341-19354. https://doi.org/10.18632/oncotarget.8464

Vancouver

Buus TB, Schmidt JD, Bonefeld CM, Geisler C, Lauritsen JPH. Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus. OncoTarget. 2016 Mar 29;7(15):19341-19354. https://doi.org/10.18632/oncotarget.8464

Author

Buus, Terkild Brink ; Schmidt, Jonas Damgård ; Bonefeld, Charlotte Menné ; Geisler, Carsten ; Lauritsen, Jens Peter Holst. / Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus. In: OncoTarget. 2016 ; Vol. 7, No. 15. pp. 19341-19354.

Bibtex

@article{3b6b4bbabfe743ea898522ebe73d9778,
title = "Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus",
abstract = "Co-stimulation is an integral part of T cell signaling involved in almost all facets of T cell biology. While much is known about co-stimulation in differentiation and function of conventional αβ T cells, less is known about how co-stimulation affects the development and programming of γδ T cells. In this study, we have investigated the role of inducible T cell co-stimulator (ICOS) on the development of γδ T cells. We show that ICOS is expressed by a population of immature Vγ2+CD45RBlow γδ T cells predisposed to interleukin-17 (IL-17) production. We found that treatment with ICOS specific antibodies drastically reduces fetal development of IL-17-producing γδ T cells by agonistic actions, and that ICOS deficient mice have a significant increase in the population of IL-17-producing Vγ2+ γδ T cells in the thymus, spleen, lymph nodes and skin and exhibit exacerbated sensitization responses to 2,4-dinitrofluorobenzene. In conclusion, this study demonstrates that development of IL-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus.",
keywords = "Development, ICOS, Immune response, Immunity, Immunology and Microbiology Section, Interleukin-17, Thymus, γδ T cell",
author = "Buus, {Terkild Brink} and Schmidt, {Jonas Damg{\aa}rd} and Bonefeld, {Charlotte Menn{\'e}} and Carsten Geisler and Lauritsen, {Jens Peter Holst}",
year = "2016",
month = mar,
day = "29",
doi = "10.18632/oncotarget.8464",
language = "English",
volume = "7",
pages = "19341--19354",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "15",

}

RIS

TY - JOUR

T1 - Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus

AU - Buus, Terkild Brink

AU - Schmidt, Jonas Damgård

AU - Bonefeld, Charlotte Menné

AU - Geisler, Carsten

AU - Lauritsen, Jens Peter Holst

PY - 2016/3/29

Y1 - 2016/3/29

N2 - Co-stimulation is an integral part of T cell signaling involved in almost all facets of T cell biology. While much is known about co-stimulation in differentiation and function of conventional αβ T cells, less is known about how co-stimulation affects the development and programming of γδ T cells. In this study, we have investigated the role of inducible T cell co-stimulator (ICOS) on the development of γδ T cells. We show that ICOS is expressed by a population of immature Vγ2+CD45RBlow γδ T cells predisposed to interleukin-17 (IL-17) production. We found that treatment with ICOS specific antibodies drastically reduces fetal development of IL-17-producing γδ T cells by agonistic actions, and that ICOS deficient mice have a significant increase in the population of IL-17-producing Vγ2+ γδ T cells in the thymus, spleen, lymph nodes and skin and exhibit exacerbated sensitization responses to 2,4-dinitrofluorobenzene. In conclusion, this study demonstrates that development of IL-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus.

AB - Co-stimulation is an integral part of T cell signaling involved in almost all facets of T cell biology. While much is known about co-stimulation in differentiation and function of conventional αβ T cells, less is known about how co-stimulation affects the development and programming of γδ T cells. In this study, we have investigated the role of inducible T cell co-stimulator (ICOS) on the development of γδ T cells. We show that ICOS is expressed by a population of immature Vγ2+CD45RBlow γδ T cells predisposed to interleukin-17 (IL-17) production. We found that treatment with ICOS specific antibodies drastically reduces fetal development of IL-17-producing γδ T cells by agonistic actions, and that ICOS deficient mice have a significant increase in the population of IL-17-producing Vγ2+ γδ T cells in the thymus, spleen, lymph nodes and skin and exhibit exacerbated sensitization responses to 2,4-dinitrofluorobenzene. In conclusion, this study demonstrates that development of IL-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus.

KW - Development

KW - ICOS

KW - Immune response

KW - Immunity

KW - Immunology and Microbiology Section

KW - Interleukin-17

KW - Thymus

KW - γδ T cell

U2 - 10.18632/oncotarget.8464

DO - 10.18632/oncotarget.8464

M3 - Journal article

C2 - 27235509

AN - SCOPUS:84964747492

VL - 7

SP - 19341

EP - 19354

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -

ID: 168886821